Invivomab rat igg2a isotype control clone 2a3

All mice were randomized prior to treatment. Once tumors become established (average tumor size of 65 mm² or 19 mm², day 17–18 or 8 after mEER and MOC2 inoculation, respectively) treatment was initiated over two weeks. The chemoradiotherapy treatment combined a fractionated tumor-directed radiation regimen (10 X 3Gy daily) (see Supplementary Material for further details) with weekly cisplatin (83μg/mouse; Selleck Chemicals) intraperitoneal injections. The immunomodulatory treatment combined weekly intraperitoneal injections of cyclophosphamide (2 mg/mouse; TCI Chemicals) and continuous oral administration of L-NIL (0.2%; Enzo Life Sciences) in the drinking water ad libitum.
For CD8 depletion experiments, all mice received the combinatory treatment and were injected with 1 mg depleting InVivoMAb anti-mouse CD8α (clone 53–6.7; BioXCell) or InVivoMAb rat IgG2a isotype control (clone 2A3; BioXCell) 2 days prior the treatment, and further treated with weekly 250 μg antibodies for 3 consecutive weeks.

GL261 cells were a kind gift from Dr. G. Yancey Gillespie (University of Alabama at Birmingham). Cells were grown at 37°C and 5% CO₂ in DMEM/F12 media supplemented with 10% FBS and penicillin/streptomycin and L-glutamine as described.^{19 (link)} Immunotherapy antibodies anti-PD-1 (InVivoMAb clone #RMP1-14) and anti-isotype control (InVivoMab rat IgG2a isotype control clone #2A3) were purchased from BioXcell. Temozolomide was purchased from Cayman chemicals. Oraplus solution was purchased from Amazon.